Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2024-09, Vol.42 (5), p.e3306-n/a
Hauptverfasser:	Kikuchi, Taku, Tsukada, Nobuhiro, Kunisada, Kodai, Matsumoto, Chiaki, Nomura‐Yogo, Moe, Oda, Yuki, Sato, Kota, Takei, Tomomi, Ogura, Mizuki, Abe, Yu, Suzuki, Kenshi, Hosoya, Osamu, Ishida, Tadao
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Dexamethasone Dexamethasone - administration & dosage Dexamethasone - adverse effects Dexamethasone - therapeutic use Female Gene Amplification Humans Immunotherapy Inhibitor drugs Male Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Oligopeptides - administration & dosage Oligopeptides - adverse effects Oligopeptides - therapeutic use Targeted cancer therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!